InNexus Biotechnology Announces Launch Of Large Scale Primate Study Of DXL625

Main Category: Lymphoma / Leukemia
Also Included In: Pharma Industry / Biotech Industry
Article Date: 08 Aug 2008 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

InNexus Biotechnology Inc., (TSX: IXS.V; OTC Bulletin Board: IXSBF) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announced that it has launched a large scale primate study of DXL625 (CD20), the company's lead program.

"We are beginning a study in cynomolgus monkeys of DXL625, an antibody directed against the B-cell marker CD20 and enhanced in potency with our DXL(TM) technology," said Thomas Kindt, Ph.D., Chief Scientific Officer. "The test is designed to evaluate toxicity and pharmokinetics of our product and to measure B-cell depletion and recovery in this primate species. This study, which takes multiple months to complete and is part of our drug development plan will generate data moving us toward human clinical trial testing with DXL625."

"Our scientific team has made steady progress in the rapid development of our first preclinical candidate, DXL625 for the prospective treatment of Non-Hodgkin's Lymphoma," said Jeff Morhet, CEO and Chairman. "The primate study is being conducted by Covance Inc. within their world-class facilities in Wisconsin. The launch of this study marks a significant milestone achievement for the company and our lead product DXL625."

InNexus recently announced the addition of a new product designated DXLr120 (CD20). This is the third product added to the growing InNexus pipeline and was developed using new recombinant methods to produce a DXL(TM) anti-CD20 antibody. Upon questions regarding InNexus having a franchise of CD20 products using multiple methods of creation, chemical and recombinant, CEO Morhet said, "I would also think that these products could and should be bundled toward future collaborations with pharmaceutical companies and DXLr120 was developed within our partnership with Royalty Pharma."

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.

InNexus Biotechnology Inc.
http://www.ixsbio.com